Insider Selling: X4 Pharmaceuticals (NASDAQ:XFOR) CFO Sells $33,653.62 in Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CFO David Kirske sold 11,767 shares of the company’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $2.86, for a total transaction of $33,653.62. Following the completion of the transaction, the chief financial officer directly owned 155,983 shares of the company’s stock, valued at $446,111.38. This represents a 7.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

X4 Pharmaceuticals Price Performance

Shares of NASDAQ XFOR traded up $0.07 during mid-day trading on Monday, reaching $2.90. The company’s stock had a trading volume of 698,082 shares, compared to its average volume of 640,364. The firm has a market capitalization of $287.54 million, a PE ratio of -2.42 and a beta of 0.46. The company has a debt-to-equity ratio of 0.49, a current ratio of 11.30 and a quick ratio of 11.02. The stock has a fifty day moving average of $3.81 and a two-hundred day moving average of $3.98. X4 Pharmaceuticals, Inc. has a 52 week low of $2.73 and a 52 week high of $4.83.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. X4 Pharmaceuticals had a negative return on equity of 63.05% and a negative net margin of 568.80%.The company had revenue of $8.81 million for the quarter, compared to analysts’ expectations of $2.42 million. As a group, sell-side analysts anticipate that X4 Pharmaceuticals, Inc. will post -0.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of XFOR. WINTON GROUP Ltd lifted its position in X4 Pharmaceuticals by 35.8% during the second quarter. WINTON GROUP Ltd now owns 14,400 shares of the company’s stock valued at $67,000 after purchasing an additional 3,800 shares during the last quarter. Pettinga Financial Advisors LLC purchased a new stake in shares of X4 Pharmaceuticals during the 2nd quarter valued at about $47,000. SummitTX Capital L.P. purchased a new position in X4 Pharmaceuticals in the first quarter worth about $46,000. AXQ Capital LP bought a new stake in X4 Pharmaceuticals during the second quarter worth approximately $107,000. Finally, Wellington Management Group LLP bought a new stake in X4 Pharmaceuticals during the second quarter worth approximately $242,000. 72.03% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

XFOR has been the topic of a number of research reports. Weiss Ratings upgraded shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. Wells Fargo & Company started coverage on X4 Pharmaceuticals in a research report on Friday, July 10th. They set an “overweight” rating and a $11.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, X4 Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.25.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases caused by immune and hematologic dysfunction. The company’s research centers on the CXCR4 biological pathway, which regulates the movement and retention of certain immune cells in the bone marrow and other tissues.

X4’s primary product is XOLREMDI (mavorixafor), an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration in 2024 for use in people aged 12 and older with WHIM syndrome.